[go: up one dir, main page]

HK1216858A1 - 包含硝酰基供體的醫藥組合物 - Google Patents

包含硝酰基供體的醫藥組合物

Info

Publication number
HK1216858A1
HK1216858A1 HK16104922.7A HK16104922A HK1216858A1 HK 1216858 A1 HK1216858 A1 HK 1216858A1 HK 16104922 A HK16104922 A HK 16104922A HK 1216858 A1 HK1216858 A1 HK 1216858A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
nitroxyl donors
nitroxyl
donors
pharmaceutical
Prior art date
Application number
HK16104922.7A
Other languages
English (en)
Inventor
Vincent Jacob Kalish
John Reardon
Frederick Arthur Brookfield
Stephen Martin Courtney
Lisa Marie Frost
John P Toscano
Original Assignee
Cardioxyl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardioxyl Pharmaceuticals Inc filed Critical Cardioxyl Pharmaceuticals Inc
Publication of HK1216858A1 publication Critical patent/HK1216858A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK16104922.7A 2013-01-18 2016-04-29 包含硝酰基供體的醫藥組合物 HK1216858A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361754237P 2013-01-18 2013-01-18
US201361782781P 2013-03-14 2013-03-14
PCT/US2014/012089 WO2014113700A1 (en) 2013-01-18 2014-01-17 Pharmaceutical compositions comprising nitroxyl donors

Publications (1)

Publication Number Publication Date
HK1216858A1 true HK1216858A1 (zh) 2016-12-09

Family

ID=50064795

Family Applications (3)

Application Number Title Priority Date Filing Date
HK16104922.7A HK1216858A1 (zh) 2013-01-18 2016-04-29 包含硝酰基供體的醫藥組合物
HK16104921.8A HK1216857A1 (zh) 2013-01-18 2016-04-29 具有改善的治療指數的硝酰基供體
HK18110676.0A HK1251170B (zh) 2013-01-18 2018-08-20 具有改善的治療指數的硝酰基供體

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK16104921.8A HK1216857A1 (zh) 2013-01-18 2016-04-29 具有改善的治療指數的硝酰基供體
HK18110676.0A HK1251170B (zh) 2013-01-18 2018-08-20 具有改善的治療指數的硝酰基供體

Country Status (29)

Country Link
US (13) US10245249B2 (zh)
EP (5) EP2945620B1 (zh)
JP (5) JP6533159B2 (zh)
KR (2) KR102177899B1 (zh)
CN (4) CN105142627B (zh)
AU (5) AU2014207404B2 (zh)
BR (2) BR112015017251B1 (zh)
CA (2) CA2898445C (zh)
CY (3) CY1120535T1 (zh)
DK (3) DK2945621T3 (zh)
ES (4) ES2705240T3 (zh)
HK (3) HK1216858A1 (zh)
HR (3) HRP20180121T1 (zh)
HU (3) HUE041861T2 (zh)
IL (4) IL239906B (zh)
LT (3) LT3284463T (zh)
MX (2) MX373176B (zh)
NZ (4) NZ748769A (zh)
PL (3) PL3284463T3 (zh)
PT (3) PT2945620T (zh)
RS (3) RS59434B1 (zh)
RU (3) RU2676277C2 (zh)
SG (6) SG10201802862WA (zh)
SI (3) SI2945620T1 (zh)
SM (3) SMT201900575T1 (zh)
TR (1) TR201802211T4 (zh)
TW (3) TWI619491B (zh)
WO (2) WO2014113700A1 (zh)
ZA (2) ZA201505090B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5548869B2 (ja) 2006-03-17 2014-07-16 ジョンズ ホプキンス ユニバーシティ スクール オブ メディシン 新規で生理学的に有用なニトロキシル供与体としてのｎ−ヒドロキシルスルホンアミド誘導体
JP6177246B2 (ja) 2011-10-17 2017-08-09 ザ・ジョンズ・ホプキンス・ユニバーシティ ヒドロキシルアミンで置換された、ｈｎｏ供与体としてのメルドラム酸、バルビツール酸、及びピラゾロンの誘導体
BR112015017251B1 (pt) * 2013-01-18 2021-10-26 Cardioxyl Pharmaceuticals, Inc. Composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
WO2015183839A1 (en) 2014-05-27 2015-12-03 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
JP2018526448A (ja) 2015-09-07 2018-09-13 浙江華海薬業股▲フン▼有限公司 一酸化窒素を放出可能なプロドラッグ分子
CN108368038A (zh) 2015-10-19 2018-08-03 卡尔迪奥克斯尔制药公司 作为硝酰基供体的n-羟基磺酰胺衍生物
WO2017070081A1 (en) 2015-10-19 2017-04-27 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US10913728B2 (en) 2016-07-28 2021-02-09 The Johns Hopkins University O-substituted hydroxamic acids
KR20190103281A (ko) 2017-01-03 2019-09-04 카르디옥실 파마슈티칼스 인코포레이티드 니트록실 공여 화합물의 투여 방법
CA3057940A1 (en) * 2017-04-18 2018-10-25 Genfit Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent
CN116283762A (zh) * 2023-03-28 2023-06-23 昆山市第一人民医院 一种用于制备白鲜碱的中间体化合物及其制备方法、白鲜碱的制备方法
WO2025043108A1 (en) 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US1021340A (en) 1911-10-14 1912-03-26 William A Scott Means for attaching binding-posts to dry batteries.
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
EP0188040B1 (en) 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0828240B2 (ja) 1990-05-25 1996-03-21 矢崎総業株式会社 電線相互の圧着接続構造及び圧着接続方法
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
BR9506549A (pt) * 1994-01-19 1997-10-14 Byk Nederland Bv Derivados de benzilamina contendo grupos nitróxi e sua aplicação para o tratamento de enfermidades cardiovasculares bem como de pressão interna dos olhos elevada
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
JPH10142729A (ja) 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
TR200001121T2 (tr) 1997-10-24 2000-09-21 Shionogi & Co., Ltd. Antiromatizmal madde.
DE69906397T2 (de) * 1998-01-16 2004-02-19 F. Hoffmann-La Roche Ag Benzosulfonderivate
US6295153B1 (en) 1998-06-04 2001-09-25 Board Of Regents, The University Of Texas System Digital optical chemistry micromirror imager
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6638534B1 (en) 1998-07-28 2003-10-28 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
CA2436526C (en) * 2000-12-13 2010-10-19 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production
EP1219306A1 (en) 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
CA2554771A1 (en) 2004-01-30 2005-08-18 Johns Hopkins University Nitroxyl progenitor compounds and methods of use
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
CA2613477C (en) 2005-06-23 2013-12-03 Johns Hopkins University Thiol-sensitive positive inotropes
JP5548869B2 (ja) 2006-03-17 2014-07-16 ジョンズ ホプキンス ユニバーシティ スクール オブ メディシン 新規で生理学的に有用なニトロキシル供与体としてのｎ−ヒドロキシルスルホンアミド誘導体
WO2007120839A2 (en) 2006-04-13 2007-10-25 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
BRPI0817562A2 (pt) 2007-09-26 2017-05-02 Cardioxyl Pharmaceuticals Inc derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis
WO2009137717A1 (en) 2008-05-07 2009-11-12 Cardioxyl Pharmaceuticals Inc. Novel nitroso compounds as nitroxyl donors and methods of use thereof
US20110160200A1 (en) 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
MX356796B (es) 2009-12-07 2018-06-14 Cardioxyl Pharmaceuticals Inc Derivados de hidroxilamina bis-acilados.
JP5826762B2 (ja) 2009-12-07 2015-12-02 ザ ジョンズ ホプキンス ユニバーシティ Ｎ−アシルオキシスルホンアミドおよびｎ−ヒドロキシ−ｎ−アシルスルホンアミド誘導体
JP6177246B2 (ja) 2011-10-17 2017-08-09 ザ・ジョンズ・ホプキンス・ユニバーシティ ヒドロキシルアミンで置換された、ｈｎｏ供与体としてのメルドラム酸、バルビツール酸、及びピラゾロンの誘導体
JP6306602B2 (ja) 2012-11-01 2018-04-04 ザ ジョンズ ホプキンス ユニバーシティ 分子内環化−脱離による制御されたｈｎｏ放出
BR112015017251B1 (pt) * 2013-01-18 2021-10-26 Cardioxyl Pharmaceuticals, Inc. Composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives

Also Published As

Publication number Publication date
ES2751922T3 (es) 2020-04-02
ZA201604798B (en) 2018-01-31
MX2015009276A (es) 2015-10-30
HUE046722T2 (hu) 2020-03-30
IL239906A0 (en) 2015-08-31
ES2705240T3 (es) 2019-03-22
US8987326B2 (en) 2015-03-24
CN105142627B (zh) 2019-06-21
US10517847B2 (en) 2019-12-31
AU2018241168A1 (en) 2018-11-01
ES2882279T3 (es) 2021-12-01
ZA201505090B (en) 2016-10-26
RU2015134583A (ru) 2017-02-22
TWI712409B (zh) 2020-12-11
RU2018143994A (ru) 2019-01-16
BR112015017251A8 (pt) 2019-10-29
US11786501B2 (en) 2023-10-17
WO2014113700A9 (en) 2014-10-09
RU2684916C2 (ru) 2019-04-16
NZ748769A (en) 2020-05-29
HRP20182144T1 (hr) 2019-03-08
US9586896B2 (en) 2017-03-07
JP6533159B2 (ja) 2019-06-19
IL258882A (en) 2018-06-28
CA2898443C (en) 2022-05-31
JP2016510326A (ja) 2016-04-07
US20150366977A1 (en) 2015-12-24
US20160031807A1 (en) 2016-02-04
WO2014113700A1 (en) 2014-07-24
TR201802211T4 (tr) 2018-03-21
HRP20180121T1 (hr) 2018-02-23
SI2945621T1 (sl) 2019-01-31
KR20150107853A (ko) 2015-09-23
SG10201802862WA (en) 2018-05-30
US11273143B2 (en) 2022-03-15
PL2945621T3 (pl) 2019-05-31
US20190224159A1 (en) 2019-07-25
AU2018203240A1 (en) 2018-05-31
IL259233B (en) 2019-10-31
CA2898445C (en) 2022-05-03
RS56968B1 (sr) 2018-05-31
SG11201505568PA (en) 2015-09-29
US20200121633A1 (en) 2020-04-23
BR112015017251A2 (pt) 2017-07-11
BR112015017241A8 (pt) 2019-10-29
IL239952A0 (en) 2015-08-31
SG10201913286PA (en) 2020-02-27
RU2676277C2 (ru) 2018-12-27
AU2014207408A1 (en) 2015-08-13
EP2945621A1 (en) 2015-11-25
EP2945621B1 (en) 2018-10-17
TW201934120A (zh) 2019-09-01
SMT201900575T1 (it) 2019-11-13
DK3284463T3 (da) 2019-10-28
US20240066002A1 (en) 2024-02-29
JP2019172682A (ja) 2019-10-10
JP2019089764A (ja) 2019-06-13
DK2945620T3 (en) 2018-02-05
HRP20191919T1 (hr) 2020-01-10
SMT201900027T1 (it) 2019-02-28
US10245249B2 (en) 2019-04-02
EP3427728B1 (en) 2021-07-07
KR20150108879A (ko) 2015-09-30
TW201442702A (zh) 2014-11-16
EP3284463B1 (en) 2019-07-24
PT3284463T (pt) 2019-10-30
RS59434B1 (sr) 2019-11-29
BR112015017241B1 (pt) 2021-10-26
EP3567031A1 (en) 2019-11-13
BR112015017251B1 (pt) 2021-10-26
LT2945621T (lt) 2019-01-10
JP6449171B2 (ja) 2019-01-09
US20190133990A1 (en) 2019-05-09
AU2014207408A8 (en) 2015-08-27
CN105142627A (zh) 2015-12-09
AU2017200147B2 (en) 2018-07-05
CA2898443A1 (en) 2014-07-24
CN110179777A (zh) 2019-08-30
US20210015784A1 (en) 2021-01-21
CN105073105B (zh) 2018-02-27
HRP20191919T8 (hr) 2021-10-01
AU2018241168B2 (en) 2020-04-02
CN105073105A (zh) 2015-11-18
RS58174B1 (sr) 2019-03-29
HUE041861T2 (hu) 2019-06-28
KR102177899B1 (ko) 2020-11-12
MX373176B (es) 2025-03-04
RU2015134581A (ru) 2017-02-27
TWI686193B (zh) 2020-03-01
US20170151210A1 (en) 2017-06-01
SG11201505567RA (en) 2015-09-29
PT2945620T (pt) 2018-02-21
IL239906B (en) 2018-05-31
JP2016505044A (ja) 2016-02-18
AU2014207408B2 (en) 2018-03-01
EP3427728A1 (en) 2019-01-16
NZ709985A (en) 2020-05-29
AU2014207404A1 (en) 2015-08-13
AU2018203240B2 (en) 2019-12-12
US20200163929A1 (en) 2020-05-28
HK1251170B (zh) 2020-04-09
PL3284463T3 (pl) 2019-12-31
ES2659969T3 (es) 2018-03-20
IL259233A (en) 2018-07-31
BR112015017241A2 (pt) 2017-07-11
EP2945620A1 (en) 2015-11-25
SMT201800088T1 (it) 2018-03-08
CN108610312A (zh) 2018-10-02
NZ748771A (en) 2019-12-20
NZ709986A (en) 2020-01-31
JP6801045B2 (ja) 2020-12-16
AU2014207404B2 (en) 2017-10-19
SI3284463T1 (sl) 2019-12-31
LT2945620T (lt) 2018-02-12
JP2017125015A (ja) 2017-07-20
SG10201913441RA (en) 2020-03-30
US20220193026A1 (en) 2022-06-23
WO2014113696A1 (en) 2014-07-24
US10548872B2 (en) 2020-02-04
MX2015009269A (es) 2015-10-30
US9968584B2 (en) 2018-05-15
DK2945621T3 (en) 2019-02-11
JP6656345B2 (ja) 2020-03-04
US20180235927A1 (en) 2018-08-23
IL239952B (en) 2018-05-31
PT2945621T (pt) 2019-01-21
CY1122177T1 (el) 2020-11-25
US11304924B2 (en) 2022-04-19
CN110179777B (zh) 2022-07-15
US9156804B2 (en) 2015-10-13
US12186301B2 (en) 2025-01-07
KR102277165B1 (ko) 2021-07-14
HUE036589T2 (hu) 2018-07-30
TWI619491B (zh) 2018-04-01
US10792273B2 (en) 2020-10-06
US10213408B2 (en) 2019-02-26
EP2945620B1 (en) 2017-11-22
EP3284463A1 (en) 2018-02-21
HK1216857A1 (zh) 2016-12-09
MX363843B (es) 2019-04-05
CY1121480T1 (el) 2020-05-29
JP6311038B2 (ja) 2018-04-11
TW201446242A (zh) 2014-12-16
US20150175566A1 (en) 2015-06-25
LT3284463T (lt) 2019-11-11
AU2014207408C1 (en) 2018-09-06
US20140206769A1 (en) 2014-07-24
SI2945620T1 (en) 2018-01-31
CA2898445A1 (en) 2014-07-24
PL2945620T3 (pl) 2018-03-30
SG10201802855TA (en) 2018-05-30
AU2017200147A1 (en) 2017-02-02
CY1120535T1 (el) 2019-07-10

Similar Documents

Publication Publication Date Title
IL288961A (en) Pharmaceutical preparations
HRP20182144T1 (hr) Farmaceutske kompozicije koje sadrže donore nitroksila
PL3030262T3 (pl) Złożona kompozycja farmaceutyczna
PL2943181T3 (pl) Kompozycje farmaceutyczne
PL3043778T3 (pl) Kompozycje farmaceutyczne zawierające refametinib
ZA201408333B (en) Pharmaceutical compositions
HK1213182A1 (zh) 外用藥物組合物
SG11201601477VA (en) Pharmaceutical composition
HRP20171888T1 (hr) Farmaceutski pripravci
HK1220143A1 (zh) 藥物組合物
GB201304699D0 (en) Pharmaceutical compositions
GB201321497D0 (en) Pharmaceutical compositions
GB201312851D0 (en) Pharmaceutical compositions
GB201304625D0 (en) New pharmaceutical composition